Literature DB >> 28836075

Antitumor evaluation and 3D-QSAR studies of a new series of the spiropyrroloquinoline isoindolinone/aza-isoindolinone derivatives by comparative molecular field analysis (CoMFA).

Masoud Sadeghzadeh1, Maryam Salahinejad2, Nahid Zarezadeh3, Mehdi Ghandi3, Maryam Keshavarz Baghery2.   

Abstract

In current study, antitumor activity of two series of the newly synthesized spiropyrroloquinoline isoindolinone and spiropyrroloquinoline aza-isoindolinone scaffolds was evaluated against three human breast normal and cancer cell lines (MCF-10A, MCF-7 and SK-BR-3) and compared with cytotoxicity values of doxorubicin and colchicine as the standard drugs. It was found that several compounds were endowed with cytotoxicity in the low micromolar range. Among these two series, compounds 6i, 6j, 6k and 7l, 7m, 7n, 7o containing 3-ethyl-1H-indole moiety were found to be highly effective against both cancer cell lines ranging from [Formula: see text] to [Formula: see text] in comparison with the corresponding analogs. Compared with human cancer cells, the most potent compounds did not show high cytotoxicity against human breast normal MCF-10A cells. Generally, most of the evaluated compounds 6a-l and 7a-o series showed more antitumor activity against SK-BR-3 than MCF-7 cells. Moreover, comparative molecular field analysis (CoMFA) as a popular tools of three-dimensional quantitative structure-activity relationship (3D-QSAR) studies was carried out on 27 spiropyrroloquinolineisoindolinone and spiropyrroloquinolineaza-isoindolinone derivatives with antitumor activity against on SK-BR-3 cells. The obtained CoMFA models showed statistically excellent performance, which also possessed good predictive ability for an external test set. The results confirm the important effect of molecular steric and electrostatic interactions of these compounds on in vitro cytotoxicity against SK-BR-3.

Entities:  

Keywords:  Antitumor agent; Breast cancer cell lines; Comparative molecular field analysis (CoMFA); Spiropyrroloquinoline aza-isoindolinone; Spiropyrroloquinoline isoindolinone

Mesh:

Substances:

Year:  2017        PMID: 28836075     DOI: 10.1007/s11030-017-9778-z

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  26 in total

1.  Discovery and SAR of hydantoin TACE inhibitors.

Authors:  Wensheng Yu; Zhuyan Guo; Peter Orth; Vincent Madison; Lei Chen; Chaoyang Dai; Robert J Feltz; Vinay M Girijavallabhan; Seong Heon Kim; Joseph A Kozlowski; Brian J Lavey; Dansu Li; Daniel Lundell; Xiaoda Niu; John J Piwinski; Janeta Popovici-Muller; Razia Rizvi; Kristin E Rosner; Bandarpalle B Shankar; Neng-Yang Shih; M Arshad Siddiqui; Jing Sun; Ling Tong; Shelby Umland; Michael K C Wong; De-yi Yang; Guowei Zhou
Journal:  Bioorg Med Chem Lett       Date:  2010-02-04       Impact factor: 2.823

2.  Asymmetric synthesis of 3-substituted isoindolinones: application to the total synthesis of (+)-lennoxamine.

Authors:  Daniel L Comins; Stefan Schilling; Yanchen Zhang
Journal:  Org Lett       Date:  2005-01-06       Impact factor: 6.005

3.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.

Authors:  Ian R Hardcastle; Shafiq U Ahmed; Helen Atkins; Gillian Farnie; Bernard T Golding; Roger J Griffin; Sabrina Guyenne; Claire Hutton; Per Källblad; Stuart J Kemp; Martin S Kitching; David R Newell; Stefano Norbedo; Julian S Northen; Rebecca J Reid; K Saravanan; Henriëtte M G Willems; John Lunec
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

4.  Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.

Authors:  Qing Y Zhang; Jian Wan; Xin Xu; Guang F Yang; Yan L Ren; Jun J Liu; Hui Wang; Yu Guo
Journal:  J Comb Chem       Date:  2007 Jan-Feb

5.  Virtual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using Topomer CoMFA.

Authors:  Richard D Cramer; Phillip Cruz; Gunther Stahl; William C Curtiss; Brian Campbell; Brian B Masek; Farhad Soltanshahi
Journal:  J Chem Inf Model       Date:  2008-11       Impact factor: 4.956

6.  Parallel synthesis of novel antitumor agents: 1,2,3-triazoles bearing biologically active sulfonamide moiety and their 3D-QSAR.

Authors:  Lili Ou; Shuang Han; Wenbo Ding; Ping Jia; Bo Yang; Jose L Medina-Franco; Marc A Giulianotti; Jian-Zhong Chen; Yongping Yu
Journal:  Mol Divers       Date:  2011-07-10       Impact factor: 2.943

7.  Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.

Authors:  Ian R Hardcastle; Junfeng Liu; Eric Valeur; Anna Watson; Shafiq U Ahmed; Timothy J Blackburn; Karim Bennaceur; William Clegg; Catherine Drummond; Jane A Endicott; Bernard T Golding; Roger J Griffin; Jan Gruber; Karen Haggerty; Ross W Harrington; Claire Hutton; Stuart Kemp; Xiaohong Lu; James M McDonnell; David R Newell; Martin E M Noble; Sara L Payne; Charlotte H Revill; Christiane Riedinger; Qing Xu; John Lunec
Journal:  J Med Chem       Date:  2011-02-11       Impact factor: 7.446

8.  One-pot synthesis of spiropyrroloquinoline-isoindolinone and their aza-analogs via the Ugi-4CR/metal-free intramolecular bis-annulation process.

Authors:  Mehdi Ghandi; Nahid Zarezadeh; Alireza Abbasi
Journal:  Org Biomol Chem       Date:  2015-08-14       Impact factor: 3.876

9.  Rh(II)-Catalyzed formation of pyrrolo[2,3-b]quinolines from azide-methylenecyclopropanes and isonitriles.

Authors:  Kai Chen; Xiang-Ying Tang; Min Shi
Journal:  Chem Commun (Camb)       Date:  2016-01-31       Impact factor: 6.222

10.  Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.

Authors:  J Wrobel; A Dietrich; S A Woolson; J Millen; M McCaleb; M C Harrison; T C Hohman; J Sredy; D Sullivan
Journal:  J Med Chem       Date:  1992-11-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.